Aromaticity at spike position 456 affects functional immunogenicity of SARS-CoV-2 Omicron variant receptor-binding domain
The recurrent emergence of the F456L substitution in SARS-CoV-2 Omicron sublineages has been associated with immune evasion, yet its impact on vaccine-induced immune responses remains poorly understood. Using a trimeric RBD-HR subunit vaccine platform, we investigated how residue 456 influences the functional immunogenicity of the receptor-binding domain (RBD). We found that the F456L substitution markedly reduced neutralizing antibody responses against multiple SARS-CoV-2 variants, despite maintaining comparable levels of total antigen-specific IgG, indicating a selective impairment of functional immunogenicity rather than overall antigenicity. Single-cell RNA sequencing and B-cell receptor (BCR) repertoire analyses further revealed that the F456L mutation weakened germinal center responses, reduced clonal expansion, and impaired repertoire remodeling of antigen-specific B cells. Structural modeling, biolayer interferometry, and calcium flux assays demonstrated that aromatic residues at position 456 promote effective germline BCR recognition and activation. Importantly, replacing the non-aromatic leucine residue with aromatic amino acids, including tyrosine or tryptophan, restored the neutralizing antibody-eliciting capacity of the antigen. Together, these findings identify aromaticity at residue 456 as a critical determinant of RBD functional immunogenicity and demonstrate how a single amino acid substitution can reshape B-cell responses and antibody quality. This work provides important insights for rational vaccine antigen design and advances our understanding of how site-specific mutations regulate antiviral immunity.
Authors
- Xiawei Wei (ORCID: https://orcid.org/0000-0002-6513-6422)
- Wenyan Ren (ORCID: https://orcid.org/0000-0001-6333-8496)
- Weiqi Hong (ORCID: https://orcid.org/0000-0003-1668-2301)
- Aqu Alu (ORCID: https://orcid.org/0000-0002-9981-0120)
- Zimin Chen (ORCID: https://orcid.org/0000-0002-2862-9674)
- Yishan Lu (ORCID: https://orcid.org/0000-0003-0771-3057)
- 杨景云
- Minyang Fu
- Binhan Wang
- Chunjun Ye
- Hao Zeng (ORCID: https://orcid.org/0000-0002-1831-3019)
- Du Xinyi
- Guangwen Lu (ORCID: https://orcid.org/0000-0001-7568-592X)
- Shuaiyao Lu (ORCID: https://orcid.org/0000-0003-1675-9735)
- Jiong Li (ORCID: https://orcid.org/0000-0002-3742-630X)
- Hong Lei (ORCID: https://orcid.org/0000-0001-6518-6190)
- He Cai (ORCID: https://orcid.org/0009-0006-0357-1492)
- Jie Shi (ORCID: https://orcid.org/0000-0001-7841-7541)
- Ying Hao (ORCID: https://orcid.org/0000-0001-5053-4850)
- Haiyang Chen (ORCID: https://orcid.org/0000-0001-8305-4060)
- Shi H (ORCID: https://orcid.org/0000-0002-9958-9892)
- Sheng Lin (ORCID: https://orcid.org/0000-0002-8133-4082)
- Xiya Huang
- Mengzhe Dai (ORCID: https://orcid.org/0009-0006-5734-2812)
- Dandan Peng
- Furong Qin
- Jian Liu
- Li Chen
- Yuquan Wei
- Yu Zhang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- State Key Laboratory of Biotherapy (CN)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-10-28
- DOI
- https://doi.org/10.1038/s41392-026-02939-3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00